O51544 UDP-N-acetylenolpyruvoylglucosamine reductase MolNFT, Molecular NFT on GenesisL1

UDP-N-acetylenolpyruvoylglucosamine reductase

MOLNFT AF v1 smart contract in GenesisL1 blockchain:

0xBf7491af3407816DFa88a5EA4c82e8A2B1D721eD

IPFS of NFT metadata:

bafybeick3h3rw5h5kr6hp5vsgrmsa77myey2dd6vf5gx42em6huzyf4tya/metadata.json

IPFS of structure file:

bafybeid5vswfobgoo4rkqsben7f4qrrjkoqbduxedb2aeprbbahmhk4dqi/AF-O51544-F1-model_v2.pdb

First NFT owner address (eip-55):

0xf1770e5260EEBa91B7A9E674F368eD787DE8992D

First NFT owner address (bech32):

genesis179msu5nqa6afrdafue60x68d0p773xfdve7fpn

Current NFT ID #250278 owner (web3):

0xf1770e5260EEBa91B7A9E674F368eD787DE8992D

First owner GALLERY | EVM EXPLORER | COSMOS EXPLORER

MOLNFT AF v1

NFT id:
250278
Accession (UniProt):
O51544
Name::
UDP-N-acetylenolpyruvoylglucosamine reductase
Experimental Method:
Predicted structure
Sequence source:
Borreliella burgdorferi (strain ATCC 35210 / DSM 4680 / CIP 102532 / B31)

NFT data

MolNFT AF v1 is an AlphaFold database of AI predicted Swiss-Prot protein sequences preserved as regular ERC-721 NFT tokens on GenesisL1 blockchain for public free use, research and entertainment:

https://alphafold.ebi.ac.uk/
Jumper, J., Evans, R., Pritzel, A. et al. Highly accurate protein structure prediction with AlphaFold. 
Nature 596, 583–589 (2021). https://doi.org/10.1038/s41586-021-03819-2

MOLNFT O51544 research and analysis (ICN3D with VR)

FASTA sequences

>sp|O51544|MURB_BORBU UDP-N-acetylenolpyruvoylglucosamine reductase OS=Borreliella burgdorferi (strain ATCC 35210 / DSM 4680 / CIP 102532 / B31) OX=224326 GN=murB PE=3 SV=1 MPKSLNNFLKKINIKPQTKNLANYTTYKIGNISKLFLTPKNIKEAENIFKAAIEEKIKLFILGGGSNILVNDEREIDFPIIYTGYLNKIEIHENKIVGECGADFESLCKIALDNSLSGLEFIYGLPGTLGGAVWMNARCFGNEISEILKKITFIDDKGKTICKEFKKEDFKYKISPFQNKNFFILKIELNLKKDNKKIIEEKMNKNKQARINRGHYLFPSGGSTFKNNKAFLKPSGQIIEECKLKGLSIGGATVSKYHGNFIININNATSKDIKSLIEKVKAEVYLKTGLLLEEEVLYIGFK

O51544 AF NFT

MOLNFT AF v1

NFT data

MOLNFT O51544 research and analysis (ICN3D with VR)

FASTA sequences

We use cookies on this site to enhance your user experience